NVAX (Novavax) E10: $-10.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVAX Novavax Inc NVAX
42 GF Score
Price $7.87
GF Value $3.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Novavax E10?

Novavax NVAX -1.01% 42 E10 is $-10.22 as of Jun. 2026. GuruFocus rates NVAX with a GF Score™ of 42/100 and a GF Value™ of $3.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novavax's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.320. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-10.22 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 4.70% per year. During the past 5 years, the average E10 Growth Rate was -3.20% per year. During the past 10 years, the average E10 Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novavax was 11.20% per year. The lowest was -12.00% per year. And the median was -0.65% per year.

As of today (2026-08-10), Novavax's current stock price is $7.87. Novavax's E10 for the quarter that ended in Jun. 2026 was $-10.22. Novavax's Shiller PE Ratio of today is .


Novavax  (NAS:NVAX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novavax E10 Related Terms


Novavax E10 Historical Data

* Premium members only.

The historical data trend for Novavax's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax E10 Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.16 -13.21 -13.40 -12.96 -11.45

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.40 -12.28 -11.45 -10.87 -10.22

NVAX vs JBIO, AVLN, TRAX: E10 Comparison

For the Biotechnology subindustry, Novavax's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Shiller PE Ratio falls into.


NVAX
42GF Score
Novavax Inc NVAX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.32/333.9520*333.9520
=-0.320

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

per share eps CPI Adj_EPS
201609 -4.800 241.428 -6.640
201612 -4.200 241.432 -5.809
201703 -3.200 243.801 -4.383
201706 -3.200 244.955 -4.363
201709 -3.010 246.819 -4.073
201712 -3.200 246.524 -4.335
201803 -2.800 249.554 -3.747
201806 -2.370 251.989 -3.141
201809 -2.330 252.439 -3.082
201812 -2.600 251.233 -3.456
201903 -2.110 254.202 -2.772
201906 -1.690 256.143 -2.203
201909 -0.740 256.759 -0.962
201912 -1.130 256.974 -1.468
202003 -0.580 258.115 -0.750
202006 -0.300 257.797 -0.389
202009 -3.210 260.280 -4.119
202012 -2.700 260.474 -3.462
202103 -3.050 264.877 -3.845
202106 -4.750 271.696 -5.838
202109 -4.310 274.310 -5.247
202112 -11.180 278.802 -13.392
202203 2.560 287.504 2.974
202206 -6.530 296.311 -7.360
202209 -2.150 296.808 -2.419
202212 -2.280 296.797 -2.565
202303 -3.410 301.836 -3.773
202306 0.580 305.109 0.635
202309 -1.260 307.789 -1.367
202312 -1.470 306.746 -1.600
202403 -1.050 312.332 -1.123
202406 0.990 314.175 1.052
202409 -0.760 315.301 -0.805
202412 -0.510 315.605 -0.540
202503 2.930 319.799 3.060
202506 0.620 322.561 0.642
202509 -1.250 324.800 -1.285
202512 0.110 324.054 0.113
202603 -0.060 330.213 -0.061
202606 -0.320 333.952 -0.320

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-10.22 mean?
Novavax (NVAX) has a E10 of $-10.22 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's E10 too high?
Novavax's current E10 is $-10.22. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's E10 compare to JBIO and AVLN?
Novavax's E10 of $-10.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current E10 is $-10.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.26, compared to a current price of $7.87 — trading 141.4% above its estimated fair value. The current E10 is $-10.22. Novavax's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Novavax (NVAX), the current E10 is $-10.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of $7.87 is trading 141.4% above its estimated GF Value™ of $3.26. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for NVAX:

  • E10: $-10.22
  • GF Value™: $3.26 vs. price of $7.87 (141.4% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for NVAX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.87
Price
$3.26
GF Value